News & Updates

Finerenone significantly reduces albuminuria vs placebo and maintains a manageable safety profile in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD) receiving background therapy with renin-angiotensin-aldosterone system inhibitors (RAASi), the phase III FINE-ONE trial has shown. These findings represent an important step forward since RAASi were introduced for renoprotection in T1D more than 30 years ago.

In the prespecified subgroup analysis of the VESALIUS-CV trial, evolocumab significantly reduced the risk of first major adverse cardiovascular (CV) events (MACE) in individuals without known significant atherosclerosis and with diabetes.